Clinicopathologic characteristics in patients with progression
PD | P | ||
---|---|---|---|
No (n = 26) | Yes (n = 6) | ||
Age, median (range) | 52 (21–76) | 59 (52–71) | 0.049* |
Sex | |||
Male | 18 (90%) | 2 (10%) | 0.17 |
Female | 8 (66.7%) | 4 (33.3%) | — |
Race | |||
White | 24 (82.8%) | 5 (17.2%) | 0.48 |
Black | 0 (0%) | 1 (100%) | — |
Hispanic | 1 (100%) | 0 (0%) | — |
Asian | 1 (100%) | 0 (0%) | — |
Smoking status | |||
Never smoker | 12 (92.3%) | 1 (7.7%) | 0.17 |
Former smoker | 8 (88.9%) | 1 (11.1%) | — |
Current smoker | 6 (60%) | 4 (40%) | — |
Differentiation | |||
Well | 1 (100%) | 0 (0%) | 0.70 |
Moderate | 7 (87.5%) | 1 (12.5%) | — |
Poorly | 11 (84.6%) | 2 (15.4%) | — |
Moderately well | 1 (50%) | 1 (50%) | — |
Poorly moderately | 2 (100%) | 0 (0%) | — |
T stage | |||
T1–T2 | 18 (86%) | 3 (14%) | 0.003 |
T3–T4 | 8 (73%) | 3 (27%) | — |
N stage | |||
N2B | 19 (90.5%) | 2 (9.5%) | 0.090 |
N2C | 5 (62.5%) | 3 (37.5%) | — |
N3 | 1 (50%) | 1 (50%) | — |
EGFR† | |||
0 | 0 (0%) | 0 (0%) | 0.78 |
1+ | 4 (100%) | 0 (0%) | |
2+ | 5 (100%) | 0 (0%) | |
3+ | 37 (82.2%) | 8 (17.8%) | |
HPV‡ | |||
HPV positive | 12 (100%) | 0 (0%) | 0.008 |
HPV negative | 8 (57%) | 6 (43%) |